{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T14:41:59Z","timestamp":1793457719013,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s11864-025-01317-5","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T09:05:26Z","timestamp":1745399126000},"page":"375-384","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future"],"prefix":"10.1007","volume":"26","author":[{"given":"Ann","family":"Ayzman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell K.","family":"Pachynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa A.","family":"Reimers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"issue":"3","key":"1317_CR1","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s11523-020-00720-2","volume":"15","author":"S Chowdhury","year":"2020","unstructured":"Chowdhury S, Bjartell A, Lumen N, Maroto P, Paiss T, Gomez-Veiga F, et al. Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer: The prostate cancer registry. Target Oncol. 2020;15(3):301\u201315.","journal-title":"Target Oncol"},{"issue":"8","key":"1317_CR2","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.1016\/S1470-2045(18)30534-5","volume":"19","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, Violet J, Hicks RJ, Sandhu S. [(177)Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer - Author\u2019s reply. Lancet Oncol. 2018;19(8):e373.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1317_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41391-021-00394-5","volume":"25","author":"F Wang","year":"2022","unstructured":"Wang F, Li Z, Feng X, Yang D, Lin M. Advances in PSMA-targeted therapy for prostate cancer. Prostate Cancer Prostatic Dis. 2022;25(1):11\u201326.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"1317_CR4","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41391-021-00340-5","volume":"24","author":"J Stultz","year":"2021","unstructured":"Stultz J, Fong L. How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2021;24(3):697\u2013717.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5","key":"1317_CR5","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.cell.2019.10.029","volume":"179","author":"S Jiao","year":"2019","unstructured":"Jiao S, Subudhi SK, Aparicio A, Ge Z, Guan B, Miura Y, et al. Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy. Cell. 2019;179(5):1177-90e13.","journal-title":"Cell"},{"issue":"12","key":"1317_CR6","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, et al. 225Ac-PSMA-617 for PSMA-Targeted alpha-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2016;57(12):1941\u20134.","journal-title":"J Nucl Med"},{"issue":"10","key":"1317_CR7","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.2967\/jnumed.117.191395","volume":"58","author":"C Kratochwil","year":"2017","unstructured":"Kratochwil C, Bruchertseifer F, Rathke H, Bronzel M, Apostolidis C, Weichert W, et al. Targeted alpha-Therapy of Metastatic Castration-Resistant Prostate Cancer with (225)Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding. J Nucl Med. 2017;58(10):1624\u201331.","journal-title":"J Nucl Med"},{"key":"1317_CR8","doi-asserted-by":"publisher","first-page":"175628722311822","DOI":"10.1177\/17562872231182219","volume":"15","author":"KK Zarrabi","year":"2023","unstructured":"Zarrabi KK, Narayan V, Mille PJ, Zibelman MR, Miron B, Bashir B, et al. Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer. Ther Adv Urol. 2023;15:17562872231182220.","journal-title":"Ther Adv Urol"},{"issue":"17","key":"1317_CR9","doi-asserted-by":"publisher","first-page":"5981","DOI":"10.1073\/pnas.0502101102","volume":"102","author":"MI Davis","year":"2005","unstructured":"Davis MI, Bennett MJ, Thomas LM, Bjorkman PJ. Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc Natl Acad Sci U S A. 2005;102(17):5981\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"1317_CR10","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.eururo.2023.11.018","volume":"85","author":"M Corpetti","year":"2024","unstructured":"Corpetti M, Muller C, Beltran H, de Bono J, Theurillat JP. Prostate-Specific Membrane Antigen-Targeted Therapies for Prostate Cancer: Towards Improving Therapeutic Outcomes. Eur Urol. 2024;85(3):193\u2013204.","journal-title":"Eur Urol"},{"issue":"12","key":"1317_CR11","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385(12):1091\u2013103.","journal-title":"N Engl J Med"},{"issue":"6","key":"1317_CR12","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1470-2045(23)00158-4","volume":"24","author":"K Fizazi","year":"2023","unstructured":"Fizazi K, Herrmann K, Krause BJ, Rahbar K, Chi KN, Morris MJ, et al. Health-related quality of life and pain outcomes with [(177)Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24(6):597\u2013610.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1317_CR13","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.eururo.2023.12.004","volume":"85","author":"KN Chi","year":"2024","unstructured":"Chi KN, Armstrong AJ, Krause BJ, Herrmann K, Rahbar K, de Bono JS, et al. Safety Analyses of the Phase 3 VISION Trial of [(177)Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2024;85(4):382\u201391.","journal-title":"Eur Urol"},{"issue":"10459","key":"1317_CR14","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, et al. (177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024;404(10459):1227\u201339.","journal-title":"Lancet"},{"issue":"1","key":"1317_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s44276-024-00065-7","volume":"2","author":"JB Schnog","year":"2024","unstructured":"Schnog JB, Duits AJ, Samson MJ. Design issues with lutetium-177 PSMA-617 registration studies that bias the outcome of the experimental arm reflect an increasing misalignment of contemporary oncology trials with true patient benefit. BJC Rep. 2024;2(1):45.","journal-title":"BJC Rep"},{"issue":"11","key":"1317_CR16","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/S1470-2045(23)00451-5","volume":"24","author":"R Aggarwal","year":"2023","unstructured":"Aggarwal R, Starzinski S, de Kouchkovsky I, Koshkin V, Bose R, Chou J, et al. Single-dose (177)Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial. Lancet Oncol. 2023;24(11):1266\u201376.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1317_CR17","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","volume":"25","author":"L Emmett","year":"2024","unstructured":"Emmett L, Subramaniam S, Crumbaker M, Nguyen A, Joshua AM, Weickhardt A, et al. [(177)Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2024;25(5):563\u201371.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1317_CR18","doi-asserted-by":"publisher","first-page":"849","DOI":"10.7150\/thno.14744","volume":"6","author":"KL Chatalic","year":"2016","unstructured":"Chatalic KL, Heskamp S, Konijnenberg M, Molkenboer-Kuenen JD, Franssen GM, Clahsen-van Groningen MC, et al. Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent. Theranostics. 2016;6(6):849\u201361.","journal-title":"Theranostics"},{"key":"1317_CR19","unstructured":"Mutevelic S, Patterson M. Curium announces ECLIPSE trial has met primary endpoint, demonstrating a statistically significant and clinically meaningful benefit for patients with PSMA-positive metastatic castration resistant prostate cancer. Curium Pharma Press Release. 2024. https:\/\/www.curiumpharma.com\/2024\/11\/13\/eclipse-tiral-psma-prostate-cancer\/."},{"key":"1317_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.annonc.2024.08.2308","volume":"35","author":"AO Sartor","year":"2024","unstructured":"Sartor AO, Jiang DM, Smoragiewicz M, Zibelman M, Flechon A, El-Haddad G, Abikhzer G, Saad F, Tutrone R, Tagawa ST, Metser U, Calais J, Hansen AR, Wu W, Jensen J, Trieu CR, Fleshner N, Teslenko I, Provost JG, Chi KN. LBA65 - Efficacy of 177Lu-PNT2002 in PSMA-positive mCRPC following progression on an androgen-receptor pathway inhibitor (ARPI) (SPLASH). Annals Oncol. 2024;35:1\u201372.","journal-title":"Annals Oncol"},{"issue":"10","key":"1317_CR21","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.2967\/jnumed.121.263618","volume":"63","author":"M Sathekge","year":"2022","unstructured":"Sathekge M, Bruchertseifer F, Vorster M, Lawal IO, Knoesen O, Mahapane J, et al. mCRPC Patients Receiving (225)Ac-PSMA-617 Therapy in the Post-Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis. J Nucl Med. 2022;63(10):1496\u2013502.","journal-title":"J Nucl Med"},{"issue":"2","key":"1317_CR22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","volume":"25","author":"MM Sathekge","year":"2024","unstructured":"Sathekge MM, Lawal IO, Bal C, Bruchertseifer F, Ballal S, Cardaci G, et al. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study. Lancet Oncol. 2024;25(2):175\u201383.","journal-title":"Lancet Oncol"},{"key":"1317_CR23","doi-asserted-by":"publisher","first-page":"S974","DOI":"10.1016\/j.annonc.2023.09.2752","volume":"34","author":"J Shen","year":"2023","unstructured":"Shen J, Pachynski R, Nordquist LT, Adra N, Bilen MA, Aggarwal R, Reichert Z, Schweizer M, Iravani A, Aung S, Hessel C, Tagawa ST. 1804P APEX-01: First-in-human phase I\/II study of ARX517 an anti- prostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Annals Oncol. 2023;34:S974\u20135.","journal-title":"Annals Oncol"},{"issue":"7","key":"1317_CR24","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1200\/JCO.23.00573","volume":"42","author":"ST Tagawa","year":"2024","unstructured":"Tagawa ST, Thomas C, Sartor AO, Sun M, Stangl-Kremser J, Bissassar M, et al. Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of (225)Ac-J591. J Clin Oncol. 2024;42(7):842\u201351.","journal-title":"J Clin Oncol"},{"key":"1317_CR25","doi-asserted-by":"publisher","unstructured":"Tagawa ST, Sun MP, Nauseef JT, Thomas C, Castellanos SH, Thomas JE, Davidson Z, Stangl-Kremser J, Bissassar M, Palmer J, Tan A, Patel A, Molina AM, Sternberg CN, Naus DM, Osborne J, Bander NH. Phase I dose-escalation results of prostate-specific membrane antigen-targeted radionuclide therapy (PSMA-TRT) with alpha-radiolabeled antibody 225Ac-J591 and beta-radioligand 177Lu-PSMA I&T. J Clin Oncol. 2023;41(15_Suppl Abstract 5018). https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.5018.","DOI":"10.1200\/JCO.2023.41.16_suppl.5018"},{"key":"1317_CR26","doi-asserted-by":"publisher","first-page":"1399802","DOI":"10.3389\/fphar.2024.1399802","volume":"15","author":"H Lampe","year":"2024","unstructured":"Lampe H, Tam L, Hansen AR. Bi-specific T-cell engagers (BiTEs) in prostate cancer and strategies to enhance development: hope for a BiTE-r future. Front Pharmacol. 2024;15:1399802.","journal-title":"Front Pharmacol"},{"issue":"2","key":"1317_CR27","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2217\/imt-2020-0256","volume":"13","author":"HD Hummel","year":"2021","unstructured":"Hummel HD, Kufer P, Grullich C, Seggewiss-Bernhardt R, Deschler-Baier B, Chatterjee M, et al. Pasotuxizumab, a BiTE((R)) immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings. Immunotherapy. 2021;13(2):125\u201341.","journal-title":"Immunotherapy"},{"issue":"8","key":"1317_CR28","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1158\/1078-0432.CCR-23-2978","volume":"30","author":"T Dorff","year":"2024","unstructured":"Dorff T, Horvath LG, Autio K, Bernard-Tessier A, Rettig MB, Machiels JP, et al. A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2024;30(8):1488\u2013500.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1317_CR29","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.clgc.2023.02.010","volume":"21","author":"EA Lim","year":"2023","unstructured":"Lim EA, Schweizer MT, Chi KN, Aggarwal R, Agarwal N, Gulley J, et al. Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2023;21(3):366\u201375.","journal-title":"Clin Genitourin Cancer"},{"key":"1317_CR30","unstructured":"Hurley, S. LAVA reports third quarter 2024 financial results and announces pipeline reprioritization and cash runway extension into 2027. LAVA therapeutics press release. Dec 10 2024. https:\/\/ir.lavatherapeutics.com\/news-releases\/news-release-details\/lava-reports-third-quarter-2024-financial-results-and-announces."},{"key":"1317_CR31","unstructured":"Campbell, D. Janux announces doses selected for phase 1b expansion trials supported by encouraging efficacy and safety profile observed in phase 1a dose escalation for JANX007 in mCRPC. Janux therapeutics press release. Dec 2 2024. https:\/\/investors.januxrx.com\/investor-media\/news\/news-details\/2024\/Janux-Announces-Doses-Selected-for-Phase-1b-Expansion-Trials-Supported-by-Encouraging-Efficacy-and-Safety-Profile-Observed-in-Phase-1a-Dose-Escalation-for-JANX007-in-mCRPC\/default.aspx."},{"issue":"1","key":"1317_CR32","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1158\/2159-8290.CD-23-0964","volume":"14","author":"WK Kelly","year":"2024","unstructured":"Kelly WK, Danila DC, Lin CC, Lee JL, Matsubara N, Ward PJ, et al. Xaluritamig, a STEAP1 x CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study. Cancer Discov. 2024;14(1):76\u201389.","journal-title":"Cancer Discov"},{"key":"1317_CR33","doi-asserted-by":"crossref","unstructured":"Aggarwal RR, Rottey S, Bernard-Tessier A, Mellado-Gonzalez B, Kosaka T, Stadler WM, Sandhu S, Yu B, Shaw C, Ju CH, Thomson C, Aparicio A. Phase 1b study of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC). J Clin Oncol. 2024;42(suppl 16; abstr 5012). https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.5012.","DOI":"10.1200\/JCO.2024.42.16_suppl.5012"},{"issue":"3","key":"1317_CR34","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1007\/s13277-013-1253-6","volume":"35","author":"Z Shang","year":"2014","unstructured":"Shang Z, Niu Y, Cai Q, Chen J, Tian J, Yeh S, et al. Human kallikrein 2 (KLK2) promotes prostate cancer cell growth via function as a modulator to promote the ARA70-enhanced androgen receptor transactivation. Tumour Biol. 2014;35(3):1881\u201390.","journal-title":"Tumour Biol"},{"issue":"1","key":"1317_CR35","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41585-024-00900-z","volume":"22","author":"MK Bakht","year":"2025","unstructured":"Bakht MK, Beltran H. Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer. Nat Rev Urol. 2025;22(1):26\u201345.","journal-title":"Nat Rev Urol"},{"issue":"2","key":"1317_CR36","doi-asserted-by":"publisher","first-page":"e233460","DOI":"10.1148\/radiol.233460","volume":"312","author":"PH Kuo","year":"2024","unstructured":"Kuo PH, Morris MJ, Hesterman J, Kendi AT, Rahbar K, Wei XX, et al. Quantitative (68)Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following (177)Lu-PSMA-617 (VISION Trial). Radiology. 2024;312(2):e233460.","journal-title":"Radiology"},{"key":"1317_CR37","doi-asserted-by":"publisher","unstructured":"\u00a0Mattana F, Muraglia L, Barone A, Colandrea M, Saker Diffalah Y, Provera S, et al. Prostate-specific membrane antigen-targeted therapy in prostate cancer: history, combination therapies, trials, and future perspective. Cancers (Basel). 2024;16(9):1643. https:\/\/doi.org\/10.3390\/cancers16091643.","DOI":"10.3390\/cancers16091643"},{"key":"1317_CR38","doi-asserted-by":"publisher","first-page":"102748","DOI":"10.1016\/j.ctrv.2024.102748","volume":"127","author":"M Muniz","year":"2024","unstructured":"Muniz M, Loprinzi CL, Orme JJ, Koch RM, Mahmoud AM, Kase AM, et al. Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going. Cancer Treat Rev. 2024;127:102748.","journal-title":"Cancer Treat Rev"},{"issue":"21","key":"1317_CR39","doi-asserted-by":"publisher","first-page":"4449","DOI":"10.1158\/1078-0432.CCR-22-3667","volume":"29","author":"G Leclercq-Cohen","year":"2023","unstructured":"Leclercq-Cohen G, Steinhoff N, Alberti Servera L, Nassiri S, Danilin S, Piccione E, et al. Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies. Clin Cancer Res. 2023;29(21):4449\u201363.","journal-title":"Clin Cancer Res"},{"key":"1317_CR40","doi-asserted-by":"publisher","unstructured":"Dang K, Castello G, Clarke SC, Li Y, Balasubramani A, Boudreau A, et al. Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release. J Immunother Cancer. 2021;9(6):e002488. https:\/\/doi.org\/10.1136\/jitc-2021-002488.","DOI":"10.1136\/jitc-2021-002488"},{"key":"1317_CR41","doi-asserted-by":"publisher","first-page":"e14587","DOI":"10.1200\/JCO.2024.42.16_suppl.e14587","volume":"42","author":"GS Falchook","year":"2024","unstructured":"Falchook GS, McKean M, Kelly WK, Patel MR, Bupathi M, Liaw BCH, Garmezy B, Vuu I, Smith K, Gokani P, Lolkema M, Fong L. Phase 1 clinical trial of AMG 340, a prostate-specific membrane antigen (PSMA)-targeted T-cell engager with a novel low-affinity CD3 binding domain designed to mitigate toxicity for the treatment of metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2024;42:e14587.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1317_CR42","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1038\/s41416-022-01994-1","volume":"127","author":"EN Glud","year":"2022","unstructured":"Glud EN, Rasmussen M, Zhang Y, Mandrup OA, Salachan PV, Borre M, et al. Identification of a high-risk immunogenic prostate cancer patient subset as candidates for T-cell engager immunotherapy and the introduction of a novel albumin-fused anti-CD3 x anti-PSMA bispecific design. Br J Cancer. 2022;127(12):2186\u201397.","journal-title":"Br J Cancer"},{"key":"1317_CR43","doi-asserted-by":"publisher","unstructured":"Belmontes B, Sawant DV, Zhong W, Tan H, Kaul A, Aeffner F, et al. Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell-cold solid tumors. Sci Transl Med. 2021;13(608):eabd1524. https:\/\/doi.org\/10.1126\/scitranslmed.abd1524.","DOI":"10.1126\/scitranslmed.abd1524"},{"key":"1317_CR44","doi-asserted-by":"publisher","unstructured":"de Bono JS, Fong L, Beer TM, Gao X, Geynisman DM, Burris HA III, Strauss JF, Courtney KD, Quinn DI, VanderWeele DJ, Yaron Y, Law CL, Stein MN. Results of an ongoing phase 1\/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T cell engager, in patients with metastatic castration- resistant prostate cancer (mCRPC). J Clin Oncol. 2021;39(15_Suppl Abstract 5013). https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.5013.","DOI":"10.1200\/JCO.2021.39.15_suppl.5013"},{"key":"1317_CR45","doi-asserted-by":"publisher","unstructured":"Beltran H, Dowlati A, Jain P, Johnson ML, Sanborn RE, Thompson JR, Mamdani H, Schenk EL, Aggarwal RR, Sankar K, Gramza AW, Anand BS. Choudhury NJ. Interim results from a phase 1\/2 study of HPN328, a tri-specific, half-life (T1\/2) extended DLL3-targeting T cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN). J Clin Oncol. 2024;42(4_Suppl Abstract 121). https:\/\/doi.org\/10.1200\/JCO.2024.42.4_suppl.121.","DOI":"10.1200\/JCO.2024.42.4_suppl.121"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01317-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-025-01317-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01317-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T05:14:38Z","timestamp":1746508478000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-025-01317-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1317"],"URL":"https:\/\/doi.org\/10.1007\/s11864-025-01317-5","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]},"assertion":[{"value":"30 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}